NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

脊髓損傷(SCI)市場:洞察,流行病學以及2030年為止的市場預測

Spinal Cord Injury (SCI) - Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 980947
出版日期 按訂單生產 內容資訊 英文 149 Pages
商品交期: 2-10個工作天內
價格
脊髓損傷(SCI)市場:洞察,流行病學以及2030年為止的市場預測 Spinal Cord Injury (SCI) - Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 149 Pages
簡介

當脊髓受到任何損害而阻礙大腦與身體之間的通信時,就會發生脊髓損傷。在七個主要市場中,脊髓損傷的總發病率在美國最高,其次是德國和法國。西班牙的流行病例最少。由於預計將推出MC001,AST-OPC1,KP-100IT,Elezanumab和Stemirac等療法,SCI市場的動態將在未來幾年發生重大的積極轉變。

本報告提供世界主要7個國家(美國,歐洲5個國家(德國,西班牙,義大利,法國,及英國),日本)的脊髓損傷(SCI)市場相關調查,提供流行病學,市場規模和預測,成長要素及課題,治療方法·各國市場分析,競爭情形,主要企業的產品等資訊。

目錄

第1章 主要洞察

第2章 摘要整理

第3章 SWOT分析

第4章 市場概要

  • 2017年:整體市場佔有率
  • 2030年:整體市場佔有率

第5章 疾病背景和概要

  • 簡介
  • SCI的病因和概要
  • SCI和脊髓症候群的分類
  • 病理學
    • SCI相關條件
  • 併發症
  • SCI的評估
  • 生物標記

第6章 流行病學和患者人口

  • 主要調查結果
  • 前提條件與理論的根據:主要7個國家

第7章 脊髓損傷(SCI)的各國流行病學

  • 美國
    • SCI的發生案例
    • SCI的盛行率
  • 歐洲5個國家
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第8章 治療和管理

  • 其他介入
    • 貫通性脊椎外傷的管理
  • 治療後的併發症及其管理
  • 治療指南

第9章 案例研究

第10章 患者療程

第11章 未滿足需求

第12章 新治療方法

  • MC001:StemCyte
    • 產品概要
    • 其他開發活動
    • 臨床開發
    • 安全性和有效性
  • AST-OPC1: Lineage Cell Therapeutics
  • KP-100IT: Kringle Pharma
  • Elezanumab: AbbVie
  • Stemirac: Nipro Corporation

第13章 其他有潛力候選人

  • AXER-204: ReNetX Bio, Inc.
    • 產品概要
    • 其他開發活動
    • 臨床開發
  • NFX88:Neurofix

第14章 脊髓損傷:主要7個國家的市場分析

  • 主要調查結果
  • 主要7國脊髓損傷(SCI)的市場規模

第15章 各國市場預測

  • 前提條件與理論的根據
  • 美國
    • 整體市場規模
    • 不同治療市場規模
  • 歐洲5個國家
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第16章 市場成長要素

第17章 市場障礙

第18章 附錄

  • 報告的調查手法

第19章 DelveInsight的服務內容

第20章 免責聲明

第21章 關於DelveInsight

目錄
Product Code: DIMI0941

DelveInsight's 'Spinal Cord Injury-Market Insights, Epidemiology, and Market Forecast - 2030' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Spinal Cord Injury in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Spinal Cord Injury market report provides analysis regarding current treatment practices, emerging drugs like MC001, AST-OPC1, KP-100IT, Elezanumab, Stemirac and other promising candidates like AXER-204, NFX88, market share of the individual therapies, and historical, current and forecasted Spinal Cord Injury market size from 2017 to 2030, segmented by seven major markets.

The report also covers current Spinal Cord Injury treatment practice/algorithm, guidelines, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Spinal Cord Injury- Disease Understanding and Treatment Algorithm

Overview:

Spinal cord injury occurs when there is any damage to the spinal cord that blocks communication between the brain and the body. After a spinal cord injury, a person's sensory, motor, and reflex messages are affected and may not pass the spinal cord's damage. The injury could be complete or incomplete. A complete spinal cord injury causes permanent damage to the area of the spinal cord that is affected. Paraplegia or tetraplegia are results of complete spinal cord injuries, whereas an incomplete spinal cord injury refers to partial damage to the spinal cord.

SCI is characterized by sequential primary, secondary, and chronic phases. The primary injury to the spinal cord is the result of the initial trauma. The primary mechanical insult may occur from compression, shearing, laceration, stretch, distraction, hemorrhage, or vasospasm. Bone or tissue fragments from the primary injury can exacerbate the spinal cord's swelling, and add to tissue damage. After the central nervous system (CNS) injury, the acute primary and the chronic secondary damage takes place. After the initial mechanical insult, a rapid deformation of CNS tissue happens, causing immediate cell death in the epicenter of the injury site, followed by a cascade of processes leading to the secondary damage. Traumatic injury disrupts spinal white matter tracts resulting in the loss of sensory and motor function. This loss of function is generally permanent due to the limited regenerative capacity of the CNS.

Imaging using MRI or CT scans will provide information about a spinal cord injury, including the type and level of the trauma. Recent guidelines have played an important role in delineating best practices and reducing practice variation in acute clinical treatments. Current management strategies for acute SCI involve early surgical decompression and fixation, vasopressor medications for mean arterial blood pressure (MAP) augmentation to improve spinal cord perfusion, and corticosteroids.

Treatment:

Current management strategies for acute SCI involve early surgical decompression and fixation, vasopressor medications for mean arterial blood pressure (MAP) augmentation to improve spinal cord perfusion, and corticosteroids. According to recent guidelines, current treatment options for chronic spinal cord injury include neurotization or nerve bridging, neurostimulation/neuromodulation, and neuroprosthesis, cell therapy, and neurorehabilitation.

This chapter covers the details of conventional and current medical therapies available for the treatment of Spinal Cord Injury. It also provides Spinal Cord Injury treatment guidelines across the United States and Europe.

DelveInsight's Spinal Cord Injury market report gives a thorough understanding of the disease by including details such as disease definition, etiology, types, neurobiology, biomarkers and diagnosis. It also provides Spinal Cord Injury treatment pattern and treatment guidelines in the US and Europe.

Epidemiology

The Spinal Cord Injury epidemiology chapters provide insights about historical and current Spinal Cord Injury patient pool and forecasted trends for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Spinal Cord Injury epidemiology is segmented by the incidence of Spinal Cord Injury and the prevalence of Spinal Cord Injury (sub-segmented into gender, etiology and neurological level). Besides, the report includes a thorough analysis of all segments.

According to DelveInsight's , the total prevalent population of Spinal Cord Injury in seven major markets was 652,542 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2030).

Among all the seven major markets, total prevalent cases for Spinal Cord Injury were highest in the United States, followed by Germany and France. Spain accounted for the least number of prevalent cases among the 7MM.

Drug Chapters

This segment encloses the detailed analysis of the drugs in the Spinal Cord Injury pipeline. It also helps understand the Spinal Cord Injury clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.

The first-line care of a patient with SCI involves securing the airway, breathing, and circulation, followed by appropriate spinal immobilization in the field to limit further insult of the highly susceptible cord during transport. Emerging therapies like MC001, AST-OPC1, KP-100IT, Elezanumab and Stemirac are expected to bring a positive shift to the overall market.

Market Outlook

The market size of Spinal Cord Injury is expected to increase at a significant CAGR during the study period (2017-2030). Among all the seven major markets, the United States accounted for the largest Spinal Cord Injury market size. Among EU5 countries, Germany, in 2017, had the largest market size with USD 125.04 million, while Spain had the smallest market size of USD 62.42 million.

Drugs Uptake

This section focuses on the rate of uptake of the potential drugs in the Spinal Cord Injury market or expected to get launched in the market during the study period 2017-2030. The analysis covers Spinal Cord Injury market uptake by drugs; patient uptake by therapies; and sale of each drug.

It helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size. All of which will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of SCI market is anticipated to experience a major positive shift in the coming years owing to the expected launch of therapies like MC001, AST-OPC1, KP-100IT, Elezanumab and Stemirac.

Spinal Cord Injury: Pipeline Development Activities

The report provides insights into different therapeutic candidates and also analyses the key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details, and emerging therapies, concerning Spinal Cord Injury.

KOL Views

To keep up with current market trends, we take KOLs and SME's opinion working in Spinal Cord Injury domain through primary research to fill the data gaps and validate our secondary research. It will support the clients in assessing potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We have performed the competitive and market Intelligence analysis of the Spinal Cord Injury Market by using various competitive intelligence tools that include SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. Besides, the inclusion of the analysis entirely depends upon the data availability.

Report Highlights::

  • In the coming years, Spinal Cord Injury market scenario is expected to experience a positive shift across the 7MM due to a robust pipeline.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II and Phase III), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Spinal Cord Injury Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Spinal Cord Injury Pipeline Analysis
  • Spinal Cord Injury Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Spinal Cord Injury Report Key Strengths

  • 11 years Forecast
  • 7MM Coverage
  • Spinal Cord Injury Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake

Spinal Cord Injury Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Spinal Cord Injury market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Spinal Cord Injury total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Spinal Cord Injury market size during the forecast period (2017-2030)?
  • At what CAGR, the Spinal Cord Injury market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Spinal Cord Injury market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Spinal Cord Injury market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burden and unmet needs of Spinal Cord Injury?
  • What is the historical Spinal Cord Injury patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Spinal Cord Injury in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to Spinal Cord Injury?
  • Out of all 7MM countries, which country would have the highest prevalent population of Spinal Cord Injury during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current options for Spinal Cord Injury treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Spinal Cord Injury in the US, Europe, and Japan?
  • How many companies are developing therapies for the treatment of Spinal Cord Injury?
  • How many therapies are developed by each company for Spinal Cord Injury?
  • How many are emerging therapies in mid-stage, and late stage of development for Spinal Cord Injury treatment?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Spinal Cord Injury therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Spinal Cord Injury and their status?
  • What are the key designations that have been granted for the emerging therapies for Spinal Cord Injury?
  • What is the global historical and forecasted market of Spinal Cord Injury?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Spinal Cord Injury market
  • To understand the future market competition in the Spinal Cord Injury market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Spinal Cord Injury in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Spinal Cord Injury market
  • To understand the future market competition in the Spinal Cord Injury market

Which geography accounted for the largest Spinal Cord Injury market size?

The United States accounted for the largest Spinal Cord Injury market size.

What is forecasted Spinal Cord Injury size in 2030?

DelveInsight estimates an increase in Spinal Cord Injury Market Size during the study period, 2017-2030

What are the present Spinal Cord Injury market drivers?

New approaches for therapy development, Absence of approved therapy, Establishment of specialized care centers, increase in patient population

What are the Spinal Cord Injury market barriers?

Hurdles associated with gathering preclinical data, Proper trial recruitment, Demographic variations in SCI incidence, Ethical concerns associated with stem cell therapies

How many companies are developing drugs for Spinal Cord Injury?

Currently, five key pharma players are developing the drug for Spinal Cord Injury

Which are the leading companies in the Spinal Cord Injury market?

Key Players - StemCyte, Lineage Cell Therapeutics, Kringle Pharma, AbbVie, Nipro Corporation

How is epidemiology segmented for Spinal Cord Injury?

Incident cases of Spinal Cord Injury, Prevalent cases of Spinal Cord Injury (sub-segmented into gender, etiology and neurological level)

Table of Contents

1 Key Insights

2 Executive Summary of Spinal Cord Injury

3 SWOT Analysis for Spinal Cord Injury

4 Spinal Cord Injury Market Overview at a Glance

  • 4.1 Market Share (%) Distribution of Spinal Cord Injury In 2017
  • 4.2 Market Share (%) Distribution of Spinal Cord Injury In 2030

5 Disease Background and Overview

  • 5.1 Introduction
  • 5.2 Etiology and description of SCI
  • 5.3 Classification of SCI and cord syndromes
  • 5.4 Pathophysiology
    • 5.4.1 SCI associated conditions
  • 5.5 Complications
  • 5.6 Assessment of SCI
  • 5.7 Biomarkers

6 Epidemiology and Patient Population

  • 6.1 Key Findings
  • 6.2 Assumptions and Rationale: 7MM

7 Country-wise Epidemiology of Spinal Cord Injury (SCI)

  • 7.1 The United States
    • 7.1.1 Incident cases of SCI
    • 7.1.2 Prevalent cases of SCI
      • 7.1.2.1 Gender-wise Prevalence of SCI
      • 7.1.2.2 Prevalence of SCI by Causes
      • 7.1.2.3 Prevalence of SCI at Neurological Level
  • 7.2 EU-5 Countries
  • 7.3 Germany
    • 7.3.1 Incident cases of SCI
    • 7.3.2 Prevalent cases of SCI
      • 7.3.2.1 Gender-wise Prevalence of SCI
      • 7.3.2.2 Prevalence of SCI by Causes
      • 7.3.2.3 Prevalence of SCI at Neurological Level
  • 7.4 France
    • 7.4.1 Incident cases of SCI
    • 7.4.2 Prevalent cases of SCI
      • 7.4.2.1 Gender-wise Prevalence of SCI
      • 7.4.2.2 Prevalence of SCI by Causes
      • 7.4.2.3 Prevalence of SCI at Neurological Level
  • 7.5 Italy
    • 7.5.1 Incident cases of SCI
    • 7.5.2 Prevalent cases of SCI
      • 7.5.2.1 Gender-wise Prevalence of SCI
      • 7.5.2.2 Prevalence of SCI by Causes
      • 7.5.2.3 Prevalence of SCI at Neurological Level
  • 7.6 Spain
    • 7.6.1 Incident cases of SCI
    • 7.6.2 Prevalent cases of SCI
      • 7.6.2.1 Gender-wise Prevalence of SCI
      • 7.6.2.2 Prevalence of SCI by Causes
      • 7.6.2.3 Prevalence of SCI at Neurological Level
  • 7.7 The UK
    • 7.7.1 Incident cases of SCI
    • 7.7.2 Prevalent cases of SCI
      • 7.7.2.1 Gender-wise Prevalence of SCI
      • 7.7.2.2 Prevalence of SCI by Causes
      • 7.7.2.3 Prevalence of SCI at Neurological Level
  • 7.8 Japan
    • 7.8.1 Incident cases of SCI
    • 7.8.2 Prevalent cases of SCI
      • 7.8.2.1 Gender-wise Prevalence of SCI
      • 7.8.2.2 Prevalence of SCI by Causes
      • 7.8.2.3 Prevalence of SCI at Neurological Level

8 Treatment and Management

Acute Spinal Cord Injury

Chronic Spinal Cord Injury

  • 8.1 Other interventions
    • 8.1.1 Management of penetrating spine trauma
  • 8.2 Post-treatment complications and their management
  • 8.3 Treatment Guidelines

NICE Guidelines

Consortium for Spinal Cord Medicine Guidelines

9 Case Study

Penetrating Spinal Cord Injury

10 Patient Journey

11 Unmet Needs

12 Emerging Therapies

  • 12.1 MC001: StemCyte
    • 12.1.1 Product Description
    • 12.1.2 Other Developmental Activities
    • 12.1.3 Clinical Development
      • 12.1.3.1 Clinical trials information
    • 12.1.4 Safety and Efficacy
  • 12.2 AST-OPC1: Lineage Cell Therapeutics
    • 12.2.1 Product Description
    • 12.2.2 Other Developmental Activities
    • 12.2.3 Clinical Development
      • 12.2.3.1 Clinical trials information
    • 12.2.4 Safety and Efficacy
  • 12.3 KP-100IT: Kringle Pharma
    • 12.3.1 Product Description
    • 12.3.2 Other Developmental Activities
    • 12.3.3 Clinical Development
      • 12.3.3.1 Clinical trials information
    • 12.3.4 Safety and Efficacy
  • 12.4 Elezanumab: AbbVie
    • 12.4.1 Product Description
    • 12.4.2 Other Developmental Activities
    • 12.4.3 Clinical Development
      • 12.4.3.1 Clinical trials information
  • 12.5 Stemirac: Nipro Corporation
    • 12.5.1 Product Description
    • 12.5.2 Other Developmental Activities
    • 12.5.3 Clinical Development
    • 12.5.4 Safety and Efficacy

13 Other Promising Candidates

  • 13.1 AXER-204: ReNetX Bio, Inc.
    • 13.1.1 Product Description
    • 13.1.2 Other Development Activity
    • 13.1.3 Clinical Development
      • 13.1.3.1 Clinical trials information
  • 13.2 NFX88: Neurofix
    • 13.2.1 Product Description

14 Spinal Cord Injury: 7 Major Market Analysis

  • 14.1 Key Findings
  • 14.2 Market Size of Spinal Cord Injury (SCI) in 7MM

15 Market Outlook by Country

  • 15.1 Assumption and Rationale
  • 15.2 United States
    • 15.2.1 Total Market size of Spinal Cord Injury
    • 15.2.2 Spinal Cord Injury Market Size by Therapies
  • 15.3 EU5 Countries
    • 15.3.1 Germany
      • 15.3.1.1 Total Market size of Spinal Cord Injury
      • 15.3.1.2 Spinal Cord Injury Market Size by Therapies
    • 15.3.2 France
      • 15.3.2.1 Total Market size of Spinal Cord Injury
      • 15.3.2.2 Spinal Cord Injury Market Size by Therapies
    • 15.3.3 Italy
      • 15.3.3.1 Total Market size of Spinal Cord Injury
      • 15.3.3.2 Spinal Cord Injury Market Size by Therapies
    • 15.3.4 Spain
      • 15.3.4.1 Total Market size of Spinal Cord Injury
      • 15.3.4.2 Spinal Cord Injury Market Size by Therapies
    • 15.3.5 United Kingdom
      • 15.3.5.1 Total Market size of Spinal Cord Injury
      • 15.3.5.2 Spinal Cord Injury Market Size by Therapies
  • 15.4 Japan
    • 15.4.1 Total Market size of Spinal Cord Injury
    • 15.4.2 Spinal Cord Injury Market Size by Therapies

16 Market Drivers

17 Market Barriers

18 Appendix

  • 18.1 Report Methodology

19 DelveInsight Capabilities

20 Disclaimer

21 About DelveInsight

List of Tables

  • Table 1: Summary of SCI Market, Epidemiology, and Key Events (2017-2030)
  • Table 2: The American Spinal Injury Association (ASIA) impairment scale
  • Table 3: Key-stages of the spinal cord response to closed trauma
  • Table 4: Incident Cases of SCI in the United States (2017-2030)
  • Table 5: Prevalent Cases of SCI in the United States (2017-2030)
  • Table 6: Gender-wise Prevalence of SCI in the United States (2017-2030)
  • Table 7: Prevalence of SCI by Causes in the United States (2017-2030)
  • Table 8: Prevalence of SCI at Neurological Level in the United States (2017-2030)
  • Table 9: Incident Cases of SCI in Germany (2017-2030)
  • Table 10: Prevalent Cases of SCI in Germany (2017-2030)
  • Table 11: Gender-wise Prevalence of SCI in Germany (2017-2030)
  • Table 12: Prevalence of SCI by Causes in Germany (2017-2030)
  • Table 13: Prevalence of SCI at Neurological Level in Germany (2017-2030)
  • Table 14: Incident Cases of SCI in France (2017-2030)
  • Table 15: Prevalent Cases of SCI in France (2017-2030)
  • Table 16: Gender-wise Prevalence of SCI in France (2017-2030)
  • Table 17: Prevalence of SCI by Causes in France (2017-2030)
  • Table 18: Prevalence of SCI at Neurological Level in France (2017-2030)
  • Table 19: Incident Cases of SCI in Italy (2017-2030)
  • Table 20: Prevalent Cases of SCI in Italy (2017-2030)
  • Table 21: Gender-wise Prevalence of SCI in Italy (2017-2030)
  • Table 22: Prevalence of SCI by Causes in Italy (2017-2030)
  • Table 23: Prevalence of SCI at Neurological Level in Italy (2017-2030)
  • Table 24: Incident Cases of SCI in the United States (2017-2030)
  • Table 25: Prevalent Cases of SCI in Spain (2017-2030)
  • Table 26: Gender-wise Prevalence of SCI in Spain (2017-2030)
  • Table 27: Prevalence of SCI by Causes in Spain (2017-2030)
  • Table 28: Prevalence of SCI at Neurological Level in Spain (2017-2030)
  • Table 29: Incident Cases of SCI in the United Kingdom (2017-2030)
  • Table 30: Prevalent Cases of SCI in the United Kingdom (2017-2030)
  • Table 31: Gender-wise Prevalence of SCI in the United Kingdom (2017-2030)
  • Table 32: Prevalence of SCI by Causes in the United Kingdom (2017-2030)
  • Table 33: Prevalence of SCI at Neurological Level in the United Kingdom (2017-2030)
  • Table 34: Incident Cases of SCI in Japan (2017-2030)
  • Table 35: Prevalent Cases of SCI in Japan (2017-2030)
  • Table 36: Gender-wise Prevalence of SCI in Japan (2017-2030)
  • Table 37: Prevalence of SCI by Causes in Japan (2017-2030)
  • Table 38: Prevalence of SCI at Neurological Level in Japan (2017-2030)
  • Table 39: MC001, Clinical Trial Description, 2020
  • Table 40: AST-OPC1, Clinical Trial Description, 2020
  • Table 41: KP-100IT, Clinical Trial Description, 2020
  • Table 42: Elezanumab, Clinical Trial Description, 2020
  • Table 43: AXER-204, Clinical Trial Description, 2020
  • Table 44: Seven Major Market Size of Spinal Cord Injury in USD Million (2017-2030)
  • Table 45: The US Market size of Spinal Cord Injury in USD Million (2017-2030)
  • Table 46: The US market size of Spinal Cord Injury by Therapies in USD Million (2017-2030)
  • Table 47: Germany Market size of Spinal Cord Injury in USD Million (2017-2030)
  • Table 48: Germany market size of Spinal Cord Injury by Therapies in USD Million (2017-2030)
  • Table 49: France Market size of Spinal Cord Injury in USD Million (2017-2030)
  • Table 50: France market size of Spinal Cord Injury by Therapies in USD Million (2017-2030)
  • Table 51: Italy Market size of Spinal Cord Injury in USD Million (2017-2030)
  • Table 52: Italy market size of Spinal Cord Injury by Therapies in USD Million (2017-2030)
  • Table 53: Spain Market size of Spinal Cord Injury in USD Million (2017-2030)
  • Table 54: Spain market size of Spinal Cord Injury by Therapies in USD Million (2017-2030)
  • Table 55: The Spinal Cord Injury Market size of Spinal Cord Injury in USD Million (2017-2030)
  • Table 56: UK market size of Spinal Cord Injury by Therapies in USD Million (2017-2030)
  • Table 57: Japan Market size of Spinal Cord Injury in USD Million (2017-2030)
  • Table 58:Japan market size of Spinal Cord Injury by Therapies in USD Million (2017-2030)

List of Figures

  • Figure 1: SWOT Analysis
  • Figure 2: Cascade of pathophysiological mechanisms
  • Figure 3: Overview of spinal cord injury pathophysiology
  • Figure 4: Incident cases of SCI in the United States (2017-2030)
  • Figure 5: Prevalent Cases of SCI in the United States (2017-2030)
  • Figure 6: Gender-wise Prevalence of SCI in the United States (2017-2030)
  • Figure 7: Prevalence of SCI by Causes in the United States (2017-2030)
  • Figure 8: Prevalence of SCI at Neurological Level in the United States (2017-2030)
  • Figure 9: Incident cases of SCI in Germany (2017-2030)
  • Figure 10: Prevalent Cases of SCI in Germany (2017-2030)
  • Figure 11: Gender-wise Prevalence of SCI in Germany (2017-2030)
  • Figure 12: Prevalence of SCI by Causes in Germany (2017-2030)
  • Figure 13: Prevalence of SCI at Neurological Level in Germany (2017-2030)
  • Figure 14: Incident cases of SCI in France (2017-2030)
  • Figure 15: Prevalent Cases of SCI in France (2017-2030)
  • Figure 16: Gender-wise Prevalence of SCI in France (2017-2030)
  • Figure 17: Prevalence of SCI by Causes in France (2017-2030)
  • Figure 18: Prevalence of SCI at Neurological Level in France (2017-2030)
  • Figure 19: Incident cases of SCI in Italy (2017-2030)
  • Figure 20: Prevalent Cases of SCI in Italy (2017-2030)
  • Figure 21: Gender-wise Prevalence of SCI in Italy (2017-2030)
  • Figure 22: Prevalence of SCI by Causes in Italy (2017-2030)
  • Figure 23: Prevalence of SCI at Neurological Level in Italy(2017-2030)
  • Figure 24: Incident cases of SCI in Spain (2017-2030)
  • Figure 25: Prevalent Cases of SCI in Spain(2017-2030)
  • Figure 26: Gender-wise Prevalence of SCI in Spain (2017-2030)
  • Figure 27: Prevalence of SCI by Causes in Spain (2017-2030)
  • Figure 28: Prevalence of SCI at Neurological Level in Spain (2017-2030)
  • Figure 29: Incident cases of SCI in the United Kingdom (2017-2030)
  • Figure 30: Prevalent Cases of SCI in the United Kingdom (2017-2030)
  • Figure 31: Gender-wise Prevalence of SCI in the United Kingdom (2017-2030)
  • Figure 32: Prevalence of SCI by Causes in the United Kingdom (2017-2030)
  • Figure 33: Prevalence of SCI at Neurological Level in the United Kingdom (2017-2030)
  • Figure 34: Incident cases of SCI in Japan (2017-2030)
  • Figure 35: Prevalent Cases of SCI in Japan (2017-2030)
  • Figure 36: Gender-wise Prevalence of SCI in Japan (2017-2030)
  • Figure 37: Prevalence of SCI by Causes in Japan (2017-2030)
  • Figure 38: Prevalence of SCI at Neurological Level in Japan (2017-2030)
  • Figure 39: Patient Journey for management of SCI
  • Figure 40: Unmet Needs
  • Figure 41: 7 Major Market Size of Spinal Cord Injury in USD Million (2017-2030)
  • Figure 42: Market Size of SPINAL CORD INJURY in the United States, USD Millions (2017-2030)
  • Figure 43: The US market size of Spinal Cord Injury by therapies in USD Million (2017-2030)
  • Figure 44: Market Size of Spinal Cord Injury in Germany, USD Millions (2017-2030)
  • Figure 45: Germany market size of Spinal Cord Injury by therapies in USD Million (2017-2030)
  • Figure 46: Market Size of Spinal Cord Injury in France, USD Millions (2017-2030)
  • Figure 47: France market size of Spinal Cord Injury by therapies in USD Million (2017-2030)
  • Figure 48: Market Size of Spinal Cord Injury in Italy, USD Millions (2017-2030)
  • Figure 49: Italy market size of Spinal Cord Injury by therapies in USD Million (2017-2030)
  • Figure 50: Market Size of Spinal Cord Injury in Spain, USD Millions (2017-2030)
  • Figure 51: Spain market size of Spinal Cord Injury by therapies in USD Million (2017-2030)
  • Figure 52: Market Size of Spinal Cord Injury in the UK, USD Millions (2017-2030)
  • Figure 53: The UK market size of Spinal Cord Injury by therapies in USD Million (2017-2030)
  • Figure 54: Market Size of Spinal Cord Injury in Japan, USD Millions (2017-2030)
  • Figure 55: Japan market size of Spinal Cord Injury by therapies in USD Million (2017-2030)
  • Figure 56: Market drivers for SCI
  • Figure 57:Market Barriers